Genuity Capital Markets
http://www.genuitycm.com/Genuity Capital Markets is a financial services firm providing investment banking, institutional sales and trading, and equity research to its corporate clients. The firm uses a simple Buy, Hold and Sell rating system in its research analysis.
View Older Stories View More Recent Stories
-
Obagi Medical Products to Present at Two Investor Conferences in November & December
-
Canaccord Genuity Reiterates a 'Buy' on NxStage Medical (NXTM); Take-Aways from the 2011 ASN meeting
-
Canaccord Genuity Reiterates a 'Buy' on Tranzyme (TZYM); Q3/11: Ulimorelin Pivotal Top-line Data in POI on Track for H1/12
-
Canaccord Genuity Reiterates a 'Buy' on Derma Sciences (DSCI); Q3/11 Results Solid; Direct Sales Force Expanding
-
Canaccord Genuity Maintains a 'Hold' on Vertex (VRTX); Cutting Q4 and Out-Year Incivek Estimates
-
Canaccord Genuity Reiterates a 'Buy' on China Kanghui (KH); Q3/11 Results Strong; Outperformance Across All Segments
-
Canaccord Genuity Maintains a 'Hold' on Darling International (DAR); Grinding It Out
-
Canaccord Genuity Maintains a 'Hold' on Universal Display (PANL); Updating Estimates In Line with Global OLED Macro Model
-
Canaccord Genuity Reiterates a 'Buy' on Voyager Oil & Gas (VOG); Growth Profile Intact Despite Erratic Completion Schedule
-
Canaccord Genuity Reiterates a 'Buy' on Abraxas Petroleum (AXAS); Portfolio Optimization to Enhance Liquidity in Early 2012
-
Eastern Platinum Reports Results for the Three Months Ended September 30, 2011
-
Eastern Platinum Reports Results for the Three Months Ended September 30, 2011
-
NewLink Genetics (NLNK) IPO Trades Higher
-
Canaccord Genuity Maintains a 'Hold' on Edwards Lifesciences (EW); TF Data Positive, TA Not So Much; Analyst Meeting Equivocal
-
Canaccord Genuity Reiterates a 'Buy' on Trius Therapeutics (TSRX); Q3/11 Update
-
Canaccord Genuity Reiterates a 'Buy' on Meridian Biosciences (VIVO); Post-call Thoughts From Q4
-
Canaccord Genuity Maintains a 'Buy' on Anacor Pharmaceuticals (ANAC); Q3/11 Update
-
Canaccord Genuity Maintains a 'Hold' on Darling International (DAR); Q3 First Look: Feedstock Degradation is a Dead Weight
-
Canaccord Genuity Maintains a 'Hold' on Tetra Tech (TTEK); Diversification Continues
-
Canaccord Genuity Maintains a 'Buy' on Summer Infant (SUMR); 2012 Coming Into Focus, and Growth Should Continue
-
Canaccord Genuity Maintains a 'Buy' on Descartes (DSGX); User Conference Takeaway: Buyers Cautiously Optimistic
-
Canaccord Genuity Reiterates a 'Hold' on NVIDIA (NVDA), Citing Weak PC Demand, Risk to Tegra Expectations
-
Canaccord Genuity Maintains a 'Buy' on Cogo Group (COGO); Q3/11 Results: Strong Sales but Lower Margins and Limited Visibility
-
Canaccord Genuity Reiterates a 'Buy' on Northern Oil and Gas (NOG); Shift to Higher-Impact Wells Driving Completion Variability
-
Canaccord Genuity Reiterates a 'Buy' on Magnum Hunter (MHR); Results Continue to Improve Across Liquids-rich Portfolio
-
NewLink Genetics (NLNK) Prices 6.2M Share IPO at $7/Share
-
NewLink Genetics Corporation Announces Pricing for Initial Public Offering
-
Orsu Metals Corporation Interim Results for the Period Ended September 30, 2011 (Unaudited)
-
Canaccord Financial Inc. Reports Second Quarter Fiscal 2012 Results
-
AtriCure Announces Upcoming Investor Conference Schedule
-
Qwest Energy 2011-II Flow-Through Limited Partnership Completes Final Closing
-
Qwest Energy 2011-II Flow-Through Limited Partnership Completes Final Closing
-
Monsanto Executives Detail Drivers of Company's Growth; Industry's Yield Leader Delivers Winning Harvest Results
-
Canaccord Genuity Maintains a 'Hold' on Micromet (MITI); Q3/11 Update: B-mab Dosing Regimen Set
-
Canaccord Genuity Reiterates a 'Buy' on Gen-Probe (GPRO); HPV Garnering Attention
-
Canaccord Genuity Maintains a 'Hold' on Becton Dickinson (BDX); Thoughts Post Analyst Day
-
Canaccord Genuity Reiterates a 'Buy' on AcelRx Pharmaceuticals (ACRX); Q3/11: ARX-01 on Track to Enter Phase 3 by Year End
-
Canaccord Genuity Maintains a 'Buy' on ZIOPHARM Oncology (ZIOP); Q3/11 Update
-
Canaccord Genuity Reiterates a 'Buy' on Obagi Medical Products (OMPI); Q3/11 Results Strong Despite Headwinds, 2011 Guidance Maintained
-
Canaccord Genuity Reiterates a 'Hold' on MAKO Surgical (MAKO); Q3/11 Results In Line; Systems Light, Utilization Strong, Hip Just Starting
-
Canaccord Genuity Maintains a 'Hold' on Fuel Systems Solutions (FSYS); Transitioning Off a Tough Q3;
-
Canaccord Genuity maintains a 'Hold' on Nokia (NOK); Product Execution Improving; 2012 Remains Transitional Year
-
Canaccord Genuity Maintains a 'Hold' on Ericsson (ERIC); Analyst Day Highlights New IP Revenue Potential Offset by Margin Pressure
-
Canaccord Genuity Maintains a 'Buy' on KIT Digital (KITD); Solid Quarter; Our "Clean Financials" Thesis Begins to Play Out
-
Canaccord Genuity Reiterates a 'Buy' on Spreadtrum Communications (SPRD); Strong Q3/11 Results, Raising Estimates and PT
-
Canaccord Genuity Downgrades Pan Am Silver (PAAS) to Hold
-
LeMaitre Vascular Doubles Its Stock Repurchase Program From $5mm to $10mm
-
Matrix Announces New Second Closing Date for the Matrix 2011-II National and Quebec Resource Flow Through LP
-
Matrix Announces New Second Closing Date for the Matrix 2011-II National and Quebec Resource Flow Through LP
-
Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Q3/11: Tali NDA on Track, Cerezyme Shortage Continues
